Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
European Journal of Neurology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Early Data on Long-Term Efficacy and Safety of Inotersen in Patients With Hereditary Transthyretin Amyloidosis: A 2-Year Update From the Open-Label Extension of the NEURO-TTR Trial
Eur. J. Neurol. 2020 Apr 28;[EPub Ahead of Print], TH Brannagan, AK Wang, T Coelho, M Waddington Cruz, MJ Polydefkis, PJ Dyck, V Plante-Bordeneuve, JL Berk, F Barroso, G Merlini, I Conceição, SG Hughes, J Kwoh, SW Jung, S Guthrie, M Pollock, MD Benson, M GertzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.